|
|
|
| The study on expression of LYRM4⁃AS1 and independent risk factor in glioma |
| Wang Haiyue, Song Fei, Ren Peng, Xie Ying, Li Zengning, Luo Bin |
|
|
|
|
Abstract Objective To evaluate the expression level and clinical significance of LYRM4⁃AS1 in glioma patients, as well as
its related mechanisms. Methods RNA⁃seq data and clinical data of glioma patients were obtained from the TCGA database. The
expression of LYRM4⁃AS1 in tumor and normal tissues was studied, and then the relationship between LYRM4⁃AS1 and the
clinicopathological characteristics of patients with glioma was analyzed. Kaplan⁃Meier survival curve and Cox regression analysis were
used to evaluate the clinical significance of LYRM4⁃AS1. The potential biological mechanism of LYRM4⁃AS1 was discussed through
functional enrichment analysis. Results The study found that compared with normal tissues, LYRM4⁃AS1 was highly expressed in
a variety of tumor tissues, and was related to WHO grade (P<0.001), IDH status (P<0.001), and 1p/19q coding loss (P<0.001), primary
therapy outcome (P<0.001), EGFR status (P<0.001) and age (P<0.001). Prognostic analysis found that glioma patients with
LYRM4⁃AS1 overexpressing had worse OS (HR=3.99, 95%CI=3.01-5.30, P<0.001), DSS (HR=4.00, 95%CI=2.98-5.37, P<0.001)
and PFI (HR=2.68, 95%CI=2.13-3.38, P<0.001). Multivariate Cox regression found that LYRM4⁃AS1 was an independent risk factor
for prognosis. Finally, functional enrichment analysis found that LYRM4⁃AS1 was related to inflammation and immune response.
Conclusion LYRM4⁃AS1 may be a potential diagnosis, treatment and prognostic marker, and it may play a role in the occurrence
and development of glioma through inflammation and immune response.
|
|
Received: 01 February 2021
|
|
|
|
| [1] |
1Li Zhenshui, 1Hao Chunman, 1Xu Yingxia, 2Ren Xiaohui, 3Wang Qun, 4Yu Kang, 4Chen Wei，5Guo Ruifang, 6Hu Huaidong, 7Li Zengn?. Expert consensus on ketogenic diet intervention for patients with malignant glioma[J]. Electron J Metab Nutr Cancer, 2021, 8(3): 251-256. |
|
|
|
|
